Donald A.  Denkhaus net worth and biography

Donald Denkhaus Biography and Net Worth

Donald A. Denkhaus joined our Board in February 2015 and currently chairs the Audit Committee of our Board. Since 2005, Mr. Denkhaus has been Chairman and Chief Financial Officer of The Kitchen, LLC, a company providing language dubbing and subtitling services to the media and entertainment industry. From 1970 through 2002, Mr. Denkhaus, who is a retired certified public accountant, worked for Arthur Andersen LLP, a global professional services organization, where he was an audit partner for twenty-two years and held numerous leadership positions, including as head of Andersen’s South Florida audit practice and, from 1998 through 2002, as Audit Practice Partner responsible for Andersen’s offices in Florida and Puerto Rico. From 2010 to 2013, Mr. Denkhaus was Chair of Nuovo Biologics, a privately held biotech company that was developing an antiviral drug for animal use, and, from 2004 until its sale in 2009, Mr. Denkhaus served on the board of directors and as chair of the audit committee of Noven Pharmaceuticals, a publicly-traded specialty pharmaceutical company focused on women’s health and psychiatry. Mr. Denkhaus received a Master’s in Business Administration degree with a major in finance from the University of Maryland and a Bachelors of Business Administration with a major in accounting from Kent State University.

What is Donald A. Denkhaus' net worth?

The estimated net worth of Donald A. Denkhaus is at least $6.02 million as of November 11th, 2022. Mr. Denkhaus owns 277,666 shares of Catalyst Pharmaceuticals stock worth more than $6,022,576 as of November 14th. This net worth estimate does not reflect any other investments that Mr. Denkhaus may own. Learn More about Donald A. Denkhaus' net worth.

How do I contact Donald A. Denkhaus?

The corporate mailing address for Mr. Denkhaus and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Donald A. Denkhaus' contact information.

Has Donald A. Denkhaus been buying or selling shares of Catalyst Pharmaceuticals?

Donald A. Denkhaus has not been actively trading shares of Catalyst Pharmaceuticals during the last ninety days. Most recently, Donald A. Denkhaus sold 20,000 shares of the business's stock in a transaction on Friday, November 11th. The shares were sold at an average price of $16.59, for a transaction totalling $331,800.00. Following the completion of the sale, the director now directly owns 277,666 shares of the company's stock, valued at $4,606,478.94. Learn More on Donald A. Denkhaus' trading history.

Who are Catalyst Pharmaceuticals' active insiders?

Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Catalyst Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 551,255 shares worth more than $9,231,148.44. The most recent insider tranaction occured on August, 21st when Director David S Tierney sold 15,000 shares worth more than $301,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.

Information on this page was last updated on 8/21/2024.

Donald A. Denkhaus Insider Trading History at Catalyst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2022Sell20,000$16.59$331,800.00277,666View SEC Filing Icon  
9/14/2022Sell20,000$15.34$306,800.00297,666View SEC Filing Icon  
12/27/2018Buy25,000$1.91$47,750.00225,000View SEC Filing Icon  
5/30/2018Buy20,000$3.75$75,000.00120,000View SEC Filing Icon  
6/14/2016Buy50,000$0.65$32,500.00100,000View SEC Filing Icon  
1/7/2016Buy25,000$2.03$50,750.0050,000View SEC Filing Icon  
4/27/2015Buy15,000$3.71$55,650.00View SEC Filing Icon  
3/27/2015Buy5,000$4.17$20,850.00View SEC Filing Icon  
See Full Table

Donald A. Denkhaus Buying and Selling Activity at Catalyst Pharmaceuticals

This chart shows Donald A Denkhaus's buying and selling at Catalyst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Read More

Today's Range

Now: $21.69
Low: $21.53
High: $22.73

50 Day Range

MA: $20.97
Low: $19.37
High: $23.93

2 Week Range

Now: $21.69
Low: $13.00
High: $24.27

Volume

1,226,194 shs

Average Volume

1,194,411 shs

Market Capitalization

$2.59 billion

P/E Ratio

18.38

Dividend Yield

N/A

Beta

0.75